Document:

THIS
WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”) OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE
DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE
STATE SECURITIES LAWS OR THE ISSUER SHALL HAVE RECEIVED AN OPINION OF COUNSEL
REASONABLY SATISFACTORY TO THE ISSUER THAT REGISTRATION OF SUCH SECURITIES UNDER
THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS
IS NOT REQUIRED.

     

    SERIES B
WARRANT TO PURCHASE

     

    SHARES OF
COMMON STOCK

     

    OF

     

    WEIKANG
BIO-TECHNOLOGY GROUP COMPANY, INC.

     

    Expires
January 20, 2013

    

    
      
        	
                No.: ______

              	
                Number of Shares: [_____]            

              
	
                Date
      of Issuance: January 20, 2010

              	 
      

      

    

     

    FOR VALUE
RECEIVED, the undersigned, Weikang Bio-Technology Group Company, Inc., a Nevada
corporation (together with its successors and assigns, the “Issuer”), hereby
certifies that ____________________________________ (the “Holder”) or its
registered assigns is entitled to subscribe for and purchase, during the Term
(as hereinafter defined), ______ (____) shares (subject to adjustment as
hereinafter provided) of the duly authorized, validly issued, fully paid and
non-assessable Common Stock of the Issuer, at an exercise price per share equal
to the Warrant Price then in effect, subject, however, to the provisions and
upon the terms and conditions hereinafter set forth. Capitalized terms used in
this Warrant and not otherwise defined herein shall have the respective meanings
specified in Section 9 hereof.

     

    1.  
Term. The term
of this Warrant shall commence on January 20, 2010 and shall expire at 6:00
p.m., Eastern Time, on January 20, 2013 (such period being the “Term” and such date,
the “Termination
Date”).

     

    2.  
Method of Exercise;
Payment; Issuance of New Warrant; Transfer and Exchange.

     

    (a)
  Time of
Exercise. The purchase rights represented by this Warrant may be
exercised in whole or in part during the Term for such number of shares of
Common Stock set forth above. 

     

    (b)
  Method of
Exercise. The Holder hereof may exercise this Warrant, in whole or in
part, by the surrender of this Warrant (with the exercise form attached hereto
duly executed (“Notice
of Exercise”)) at the principal office of the Issuer, and by the payment
to the Issuer of an amount of consideration therefore equal to the Warrant Price
in effect on the date of such exercise multiplied by the number of shares of
Warrant Stock with respect to which this Warrant is then being exercised,
payable at such Holder’s election (i) by certified or official bank check or by
wire transfer to an account designated by the Issuer, (ii) by “cashless
exercise” in accordance with the provisions of subsection (c) of this Section 2,
or (iii) by a combination of the foregoing methods of payment selected by the
Holder of this Warrant.

     

    (c)
  Cashless
Exercise. Notwithstanding any provision herein to the contrary and
commencing six (6) months following the Original Issue Date, if (i) the Per
Share Market Value of one share of Common Stock is greater than the Warrant
Price (at the date of calculation as set forth below) and (ii) a registration
statement under the Securities Act providing for the resale of the Warrant Stock
is not then in effect by the date such registration statement is required to be
effective pursuant to the Subscription Agreement (as defined in Section 8
hereof) or not effective at any time during the Effectiveness Period (as defined
in the Subscription Agreement) in accordance with the terms of the Subscription
Agreement, in lieu of exercising this Warrant by payment of cash, the Holder may
elect to exercise this Warrant by a cashless exercise and shall receive the
number of shares of Common Stock equal to an amount (as determined below) by
surrender of this Warrant at the principal office of the Issuer together with
the properly endorsed Notice of Exercise in which event the Issuer shall issue
to the Holder a number of shares of Common Stock computed using the following
formula:

    
      
         

      

      
        1

        
          

        

      

      
         

      

    

    

    
      
        
          	 
      	 
      
	 
      	
                  X =
      Y - (A)(Y)

                
	
                    

                	
                  B

                
	 
      	 
      	 
      
	
                    Where

                	
                  X
      =

                	
                  the
      number of shares of Common Stock to be issued to the
    Holder.

                
	 
      	 
      	 
      
	 
      	
                  Y
      =

                	
                  the
      number of shares of Warrant Stock issuable upon exercise of this Warrant
      in accordance with the terms of this Warrant by means of a cash exercise
      rather than a cashless exercise.

                
	 
      	 
      	 
      
	 
      	
                  A
      =

                	
                  the
      Warrant Price.

                
	 
      	 
      	 
      
	 
      	
                  B
      =

                	
                  the
      Per Share Market Value of one share of Common Stock on the Trading Day
      immediately preceding the date of such
election.

                

        

      

    

     

    (d)
  Issuance of
Stock Certificates. In the event of any exercise of this Warrant in
accordance with and subject to the terms and conditions hereof, certificates for
the shares of Warrant Stock so purchased shall be dated the date of such
exercise and delivered to the Holder hereof within a reasonable time, not
exceeding five (5) Trading Days after such exercise (the “Delivery Date”) or,
at the request of the Holder (provided that a registration statement under the
Securities Act providing for the resale of the Warrant Stock is then in effect
or that the shares of Warrant Stock are otherwise exempt from registration),
issued and delivered to the Depository Trust Company (“DTC”) account on the
Holder’s behalf via the Deposit Withdrawal Agent Commission System (“DWAC”) within a
reasonable time, not exceeding five (5) Trading Days after such exercise, and
the Holder hereof shall be deemed for all purposes to be the holder of the
shares of Warrant Stock so purchased as of the date of such exercise.
Notwithstanding the foregoing to the contrary, the Issuer or its transfer agent
shall only be obligated to issue and deliver the shares to the DTC on a holder’s
behalf via DWAC if such exercise is in connection with a sale or other exemption
from registration by which the shares may be issued without a restrictive
legend. The Holder shall deliver this original Warrant, or an indemnification
undertaking with respect to such Warrant in the case of its loss, theft or
destruction, at such time that this Warrant is fully exercised. With respect to
partial exercises of this Warrant, the Issuer shall keep written records for the
Holder of the number of shares of Warrant Stock exercised as of each date of
exercise.

     

    (e)
  Compensation
for Buy-In on Failure to Timely Deliver Certificates Upon Exercise. In
addition to any other rights available to the Holder, if the Issuer fails to
cause its transfer agent to transmit to the Holder a certificate or certificates
representing the Warrant Stock pursuant to an exercise on or before the Delivery
Date, and if after such date the Holder is required by its broker to purchase
(in an open market transaction or otherwise) shares of Common Stock to deliver
in satisfaction of a sale by the Holder of the Warrant Stock which the Holder
anticipated receiving upon such exercise (a “Buy-In”), then the
Issuer shall: (1) pay in cash to the Holder the amount by which (x) the Holder’s
total purchase price (including brokerage commissions, if any) for the shares of
Common Stock so purchased exceeds (y) the amount obtained by multiplying (A) the
number of shares of Warrant Stock that the Issuer was required to deliver to the
Holder in connection with the exercise at issue times (B) the price at which the
sell order giving rise to such purchase obligation was executed, and (2) at the
option of the holder, either reinstate the portion of the Warrant and equivalent
number of shares of Warrant Stock for which such exercise was not honored or
deliver to the Holder the number of shares of Common Stock that would have been
issued had the Issuer timely complied with its exercise and delivery obligations
hereunder. For example, if the Holder purchases Common Stock having a total
purchase price of $11,000 to cover a Buy-In with respect to an attempted
exercise of shares of Common Stock with an aggregate sale price giving rise to
such purchase obligation of $10,000, under clause (1) of the immediately
preceding sentence the Issuer shall be required to pay the Holder $1,000. The
Holder shall provide the Issuer written notice indicating the amounts payable to
the Holder in respect of the Buy-In, together with applicable confirmations and
other evidence reasonably requested by the Issuer. Nothing herein shall limit a
Holder’s right to pursue any other remedies available to it hereunder, at law or
in equity including, without limitation, a decree of specific performance and/or
injunctive relief with respect to the Issuer’s failure to timely deliver
certificates representing shares of Common Stock upon exercise of this Warrant
as required pursuant to the terms hereof.

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

     

    (f)
  Transferability
of Warrant. Subject to Section 2(h) hereof, this Warrant may be
transferred by a Holder, in whole or in part, to an “accredited investor” as
defined in Regulation D under the Securities Act without the consent of the
Issuer. If transferred pursuant to this paragraph, this Warrant may be
transferred on the books of the Issuer by the Holder hereof in person or by duly
authorized attorney, upon surrender of this Warrant at the principal office of
the Issuer, properly endorsed (by the Holder executing an assignment in the form
attached hereto) and upon payment of any necessary transfer tax or other
governmental charge imposed upon such transfer. This Warrant is exchangeable at
the principal office of the Issuer for Warrants to purchase the same aggregate
number of shares of Warrant Stock, each new Warrant to represent the right to
purchase such number of shares of Warrant Stock as the Holder hereof shall
designate at the time of such exchange. All Warrants issued on transfers or
exchanges shall be dated the Original Issue Date and shall be identical with
this Warrant except as to the number of shares of Warrant Stock issuable
pursuant thereto.

     

    (g)
  Continuing
Rights of Holder. The Issuer will, at the time of or at any time after
each exercise of this Warrant, upon the request of the Holder hereof,
acknowledge in writing the extent, if any, of its continuing obligation to
afford to such Holder all rights to which such Holder shall continue to be
entitled after such exercise in accordance with the terms of this Warrant, provided that if any
such Holder shall fail to make any such request, the failure shall not affect
the continuing obligation of the Issuer to afford such rights to such
Holder.

    

    (h)
  Compliance with
Securities Laws.

     

    (i)
  The Holder of this Warrant, by acceptance hereof, acknowledges that this
Warrant and the shares of Warrant Stock to be issued upon exercise hereof are
being acquired solely for the Holder’s own account and not as a nominee for any
other party, and for investment, and that the Holder will not offer, sell or
otherwise dispose of this Warrant or any shares of Warrant Stock to be issued
upon exercise hereof except pursuant to an effective registration statement, or
an exemption from registration, under the Securities Act and any applicable
state securities laws.

     

    (ii)
  Except as provided in paragraph (iii) below, this Warrant and all
certificates representing shares of Warrant Stock issued upon exercise hereof
shall be stamped or imprinted with a legend in substantially the following
form:

     

    THIS
WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”) OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE
DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE
STATE SECURITIES LAWS OR THE ISSUER SHALL HAVE RECEIVED AN OPINION OF COUNSEL
REASONABLY SATISFACTORY TO THE ISSUER THAT REGISTRATION OF SUCH SECURITIES UNDER
THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS
IS NOT REQUIRED.

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

     

    (iii)
  The Issuer agrees to reissue this Warrant or certificates representing
any of the Warrant Stock, without the legend set forth above if at such time,
prior to making any transfer of any such securities, the Holder shall give
written notice to the Issuer describing the manner and terms of such transfer.
Such proposed transfer will not be effected until: (a) either (i) the Issuer has
received an opinion of counsel reasonably satisfactory to the Issuer, to the
effect that the registration of such securities under the Securities Act is not
required in connection with such proposed transfer, (ii) a registration
statement under the Securities Act covering such proposed disposition has been
filed by the Issuer with the United States Securities and Exchange Commission
and has become effective under the Securities Act, or (iii) the Issuer has
received other evidence reasonably satisfactory to the Issuer that such
registration and qualification under the Securities Act and state securities
laws are not required; and (b) either (i) the Issuer has received an opinion of
counsel reasonably satisfactory to the Issuer, to the effect that registration
or qualification under the securities or “blue sky” laws of any state is not
required in connection with such proposed disposition, or (ii) compliance with
applicable state securities or “blue sky” laws has been effected or a valid
exemption exists with respect thereto. The Issuer will respond to any such
notice from a holder within five (5) Trading Days. In the case of any proposed
transfer under this Section 2(h), the Issuer will use reasonable efforts to
comply with any such applicable state securities or “blue sky” laws, but shall
in no event be required, (x) to qualify to do business in any state where it is
not then qualified, (y) to take any action that would subject it to tax or to
the general service of process in any state where it is not then subject, or (z)
to comply with state securities or “blue sky” laws of any state for which
registration by coordination is unavailable to the Issuer. The restrictions on
transfer contained in this Section 2(h) shall be in addition to, and not by way
of limitation of, any other restrictions on transfer contained in any other
section of this Warrant. Whenever a certificate representing the Warrant Stock
is required to be issued to the Holder without a legend, in lieu of delivering
physical certificates representing the Warrant Stock, the Issuer shall cause its
transfer agent to electronically transmit the Warrant Stock to the Holder by
crediting the account of the Holder or Holder’s Prime Broker with DTC through
its DWAC system (to the extent not inconsistent with any provisions of this
Warrant or the Subscription Agreement).

     

    (i)
  Accredited
Investor Status. In no event may the Holder exercise this Warrant in
whole or in part unless the Holder is an “accredited investor” as defined in
Regulation D under the Securities Act.

     

    3.  
Stock Fully Paid;
Reservation and Listing of Shares; Covenants.

     

    (a)
  Stock Fully
Paid. The Issuer represents, warrants, covenants and agrees that all
shares of Warrant Stock which may be issued upon the exercise of this Warrant or
otherwise hereunder will, when issued in accordance with the terms of this
Warrant, be duly authorized, validly issued, fully paid and non-assessable and
free from all taxes, liens and charges created by or through the Issuer. The
Issuer further covenants and agrees that during the period within which this
Warrant may be exercised, the Issuer will at all times have authorized and
reserved for the purpose of the issuance upon exercise of this Warrant a number
of authorized but unissued shares of Common Stock equal to at least the number
of shares of Common Stock issuable upon exercise of this Warrant without regard
to any limitations on exercise.

     

    (b)
  Reservation. If any
shares of Common Stock required to be reserved for issuance upon exercise of
this Warrant or as otherwise provided hereunder require registration or
qualification with any Governmental Authority under any federal or state law
before such shares may be so issued, the Issuer will in good faith use its best
efforts as expeditiously as possible at its expense to cause such shares to be
duly registered or qualified, in accordance with the terms and provisions of the
Subscription Agreement. If the Issuer shall list any shares of Common Stock on
any securities exchange or market it will, at its expense, list thereon, and
maintain and increase when necessary such listing, of, all shares of Warrant
Stock from time to time issued upon exercise of this Warrant or as otherwise
provided hereunder (provided that such
Warrant Stock has been registered pursuant to a registration statement under the
Securities Act then in effect), and, to the extent permissible under the
applicable securities exchange rules, all unissued shares of Warrant Stock which
are at any time issuable hereunder, so long as any shares of Common Stock shall
be so listed. The Issuer will also so list on each securities exchange or
market, and will maintain such listing of, any other securities which the Holder
of this Warrant shall be entitled to receive upon the exercise of this Warrant
if at the time any securities of the same class shall be listed on such
securities exchange or market by the Issuer.

     

    (c)
  Covenants. The Issuer
shall not by any action including, without limitation, amending the Certificate
of Incorporation or the by-laws of the Issuer, or through any reorganization,
transfer of assets, consolidation, merger, dissolution, issue or sale of
securities or any other action, avoid or seek to avoid the observance or
performance of any of the terms of this Warrant, but will at all times in good
faith assist in the carrying out of all such terms and in the taking of all such
actions as may be necessary or appropriate to protect the rights of the Holder
hereof against dilution (to the extent specifically provided herein) or
impairment. Without limiting the generality of the foregoing, the Issuer will
(i) not permit the par value, if any, of its Common Stock to exceed the then
effective Warrant Price, (ii) not amend or modify any provision of the
Certificate of Incorporation or by-laws of the Issuer in any manner that would
adversely affect the rights of the Holders of the Warrants, (iii) take all such
action as may be reasonably necessary in order that the Issuer may validly and
legally issue fully paid and nonassessable shares of Common Stock, free and
clear of any liens, claims, encumbrances and restrictions (other than as
provided herein) upon the exercise of this Warrant, and (iv) use its best
efforts to obtain all such authorizations, exemptions or consents from any
public regulatory body having jurisdiction thereof as may be reasonably
necessary to enable the Issuer to perform its obligations under this
Warrant.

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

     

    (d)
  Loss, Theft,
Destruction of Warrants. Upon receipt of evidence satisfactory to the
Issuer of the ownership of and the loss, theft, destruction or mutilation of any
Warrant and, in the case of any such loss, theft or destruction, upon receipt of
indemnity or security satisfactory to the Issuer or, in the case of any such
mutilation, upon surrender and cancellation of such Warrant, the Issuer will
make and deliver, in lieu of such lost, stolen, destroyed or mutilated Warrant,
a new Warrant of like tenor and representing the right to purchase the same
number of shares of Common Stock.

     

    (e)
  Payment of
Taxes. The Issuer will pay any documentary stamp taxes attributable to
the initial issuance of the Warrant Stock issuable upon exercise of this
Warrant; provided, however, that the
Issuer shall not be required to pay any tax or taxes which may be payable in
respect of any transfer involved in the issuance or delivery of any certificates
representing Warrant Stock in a name other than that of the Holder in respect to
which such shares are issued.

     

    4.  
Adjustment of Warrant
Price. The price at which such shares of Warrant Stock may be purchased
upon exercise of this Warrant shall be subject to adjustment from time to time
as set forth in this Section 4. The Issuer shall give the Holder notice of any
event described below which requires an adjustment pursuant to this Section 4 in
accordance with the notice provisions set forth in Section 5.

     

    (a)
  Recapitalization,
Reorganization, Reclassification, Consolidation, Merger or
Sale.

     

    (i)
  In case the Issuer after the Original Issue Date shall do any of the
following (each, a “Triggering Event”):
(a) consolidate or merge with or into any other Person and the Issuer shall not
be the continuing or surviving corporation of such consolidation or merger, or
(b) permit any other Person to consolidate with or merge into the Issuer and the
Issuer shall be the continuing or surviving Person but, in connection with such
consolidation or merger, any Capital Stock of the Issuer shall be changed into
or exchanged for Securities of any other Person or cash or any other property,
or (c) transfer all or substantially all of its properties or assets to any
other Person, or (d) effect a capital reorganization or reclassification of its
Capital Stock, then, and in the case of each such Triggering Event, proper
provision shall be made to the Warrant Price and the number of shares of Warrant
Stock that may be purchased upon exercise of this Warrant so that, upon the
basis and the terms and in the manner provided in this Warrant, the Holder of
this Warrant shall be entitled upon the exercise hereof at any time after the
consummation of such Triggering Event, to the extent this Warrant is not
exercised prior to such Triggering Event, to receive at the Warrant Price in
effect at the time immediately prior to the consummation of such Triggering
Event, in lieu of the Common Stock issuable upon such exercise of this Warrant
prior to such Triggering Event, the Securities, cash and property to which such
Holder would have been entitled upon the consummation of such Triggering Event
if such Holder had exercised the rights represented by this Warrant immediately
prior thereto (including the right of a shareholder to elect the type of
consideration it will receive upon a Triggering Event), subject to adjustments
(subsequent to such corporate action) as nearly equivalent as possible to the
adjustments provided for elsewhere in this Section 4; provided , however , the Holder
at its option may elect to receive an amount in unregistered shares of the
common stock of the surviving entity equal to the value of this Warrant
calculated in accordance with the Black-Scholes formula. Immediately upon the
occurrence of a Triggering Event, the Issuer shall notify the Holder in writing
of such Triggering Event and provide the calculations in determining the number
of shares of Warrant Stock issuable upon exercise of the new warrant and the
adjusted Warrant Price. Upon the Holder’s request, the continuing or surviving
corporation as a result of such Triggering Event shall issue to the Holder a new
warrant of like tenor evidencing the right to purchase the adjusted number of
shares of Warrant Stock and the adjusted Warrant Price pursuant to the terms and
provisions of this Section 4(a)(i).  In the event that the surviving
entity pursuant to any such Triggering Event is not a public company that is
registered pursuant to the Exchange Act of 1934, as amended, or its common stock
is not listed or quoted on a national securities exchange, national automated
quotation system or the OTC Bulletin Board, then the Holder at its option may
elect to receive an amount in unregistered shares of the common stock of the
surviving entity equal to the value of this Warrant calculated in accordance
with the Black-Scholes formula.

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

     

    (ii)
  In the event that the Holder has elected not to exercise this Warrant
prior to the consummation of a Triggering Event and has also elected not to
receive an amount in unregistered shares equal to the value of this Warrant
calculated in accordance with the Black-Scholes formula pursuant to the
provisions of Section 4(a)(i) above, so long as the surviving entity pursuant to
any Triggering Event is a company that has a class of equity securities
registered pursuant to the Exchange Act and its common stock is listed or quoted
on a national securities exchange, national automated quotation system or the
OTC Bulletin Board, the surviving entity and/or each Person (other than the
Issuer) which may be required to deliver any Securities, cash or property upon
the exercise of this Warrant as provided herein shall assume, by written
instrument delivered to, and reasonably satisfactory to, the Holder of this
Warrant, (A) the obligations of the Issuer under this Warrant (and if the Issuer
shall survive the consummation of such Triggering Event, such assumption shall
be in addition to, and shall not release the Issuer from, any continuing
obligations of the Issuer under this Warrant) and (B) the obligation to deliver
to such Holder such Securities, cash or property as, in accordance with the
foregoing provisions of this subsection (a), such Holder shall be entitled to
receive, and the surviving entity and/or each such Person shall have similarly
delivered to such Holder an opinion of counsel for the surviving entity and/or
each such Person, which counsel shall be reasonably satisfactory to such Holder,
or in the alternative, a written acknowledgement executed by the President or
Chief Financial Officer of the Issuer, stating that this Warrant shall
thereafter continue in full force and effect and the terms hereof (including,
without limitation, all of the provisions of this subsection (a)) shall be
applicable to the Securities, cash or property which the surviving entity and/or
each such Person may be required to deliver upon any exercise of this Warrant or
the exercise of any rights pursuant hereto.

     

    (b)
  Stock
Dividends, Subdivisions and Combinations. If at any time the Issuer
shall:

     

    (i)
  make or issue or set a record date for the holders of the Common Stock
for the purpose of entitling them to receive a dividend payable in, or other
distribution of, shares of Common Stock,

     

    (ii)
  subdivide its outstanding shares of Common Stock into a larger number of
shares of Common Stock, or

     

    (iii)  combine
its outstanding shares of Common Stock into a smaller number of shares of Common
Stock,

     

    then (1)
the number of shares of Common Stock for which this Warrant is exercisable
immediately after the occurrence of any such event shall be adjusted to equal
the number of shares of Common Stock which a record holder of the same number of
shares of Common Stock for which this Warrant is exercisable immediately prior
to the occurrence of such event would own or be entitled to receive after the
happening of such event, and (2) the Warrant Price then in effect shall be
adjusted to equal (A) the Warrant Price then in effect multiplied by the number
of shares of Common Stock for which this Warrant is exercisable immediately
prior to the adjustment divided by (B) the number of shares of Common Stock for
which this Warrant is exercisable immediately after such
adjustment.

     

    (c)
  Certain Other
Distributions. If at any time the Issuer shall make or issue or set a
record date for the holders of the Common Stock for the purpose of entitling
them to receive any dividend or other distribution of:

     

    (i)
   cash,

     

    (ii)
  any evidences of its indebtedness, any shares of stock of any class or
any other securities or property of any nature whatsoever (other than cash,
Common Stock Equivalents or Additional Shares of Common Stock), or

     

    (iii)
  any warrants or other rights to subscribe for or purchase any evidences
of its indebtedness, any shares of stock of any class or any other securities or
property of any nature whatsoever (other than cash, Common Stock Equivalents or
Additional Shares of Common Stock),

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

     

    then (1)
the number of shares of Common Stock for which this Warrant is exercisable shall
be adjusted to equal the product of the number of shares of Common Stock for
which this Warrant is exercisable immediately prior to such adjustment
multiplied by a fraction (A) the numerator of which shall be the Per Share
Market Value of Common Stock at the date of taking such record and (B) the
denominator of which shall be such Per Share Market Value minus the amount
allocable to one share of Common Stock of any such cash so distributable and of
the fair value (as determined in good faith by the Board of Directors of the
Issuer and supported by an opinion from an investment banking firm mutually
agreed upon by the Issuer and the Holder) of any and all such evidences of
indebtedness, shares of stock, other securities or property or warrants or other
subscription or purchase rights so distributable, and (2) the Warrant Price then
in effect shall be adjusted to equal (A) the Warrant Price then in effect
multiplied by the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to the adjustment divided by (B) the number of
shares of Common Stock for which this Warrant is exercisable immediately after
such adjustment. A reclassification of the Common Stock (other than a change in
par value, or from par value to no par value or from no par value to par value)
into shares of Common Stock and shares of any other class of stock shall be
deemed a distribution by the Issuer to the holders of its Common Stock of such
shares of such other class of stock within the meaning of this Section 4(c) and,
if the outstanding shares of Common Stock shall be changed into a larger or
smaller number of shares of Common Stock as a part of such reclassification,
such change shall be deemed a subdivision or combination, as the case may be, of
the outstanding shares of Common Stock within the meaning of Section
4(b).

    

    (e)
  Issuance of
Common Stock Equivalents. In the event the Issuer shall take a record of
the holders of its Common Stock for the purpose of entitling them to receive a
distribution of, or shall in any manner (whether directly or by assumption in a
merger in which the Issuer is the surviving corporation) issue or sell, any
Common Stock Equivalents, whether or not the rights to exchange or convert
thereunder are immediately exercisable, and the price per share for which Common
Stock is issuable upon such conversion or exchange shall be less than the
Warrant Price in effect immediately prior to the time of such issue or sale, or
if, after any such issuance of Common Stock Equivalents, the price per share for
which Additional Shares of Common Stock may be issuable thereafter is amended or
adjusted, and such price as so amended shall be less than the Warrant Price in
effect at the time of such amendment or adjustment, then the Warrant Price then
in effect shall be adjusted as provided in Section 4(d). No further adjustments
of the number of shares of Common Stock for which this Warrant is exercisable
and the Warrant Price then in effect shall be made upon the actual issue of such
Common Stock upon conversion or exchange of such Common Stock
Equivalents.

    

    (f)
  Superseding
Adjustment. If, at any time after any adjustment of the Warrant Price
then in effect shall have been made pursuant to Section 4(e) as the result of
any issuance of Common Stock Equivalents, and such Common Stock Equivalents, or
the right of conversion or exchange in such Common Stock Equivalents, shall
expire, and all of such or the right of conversion or exchange with respect to
all of such Common Stock Equivalents shall not have been converted or exercised,
then, on the date that such right of conversion or exchange of the Common Stock
Equivalents shall be set to expire, such previous adjustment shall be rescinded
and annulled and the Warrant Price then in effect shall be adjusted to the
Warrant Price in effect immediately prior to the issuance of such Common Stock
Equivalents, subject to any further adjustments pursuant to this Section
4.

     

    (g)
  Other
Provisions Applicable to Adjustments under this Section. The following
provisions shall be applicable to the making of adjustments of the number of
shares of Common Stock for which this Warrant is exercisable and the Warrant
Price then in effect provided for in this Section 4:

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

     

    (i)
  Computation of
Consideration. To the extent that any Additional Shares of Common Stock
or any Common Stock Equivalents (or any warrants or other rights therefore)
shall be issued for cash consideration, the consideration received by the Issuer
therefore shall be the amount of the cash received by the Issuer therefore, or,
if such Additional Shares of Common Stock or Common Stock Equivalents are
offered by the Issuer for subscription, the subscription price, or, if such
Additional Shares of Common Stock or Common Stock Equivalents are sold to
underwriters or dealers for public offering without a subscription offering, the
initial public offering price (in any such case subtracting any amounts paid or
receivable for accrued interest or accrued dividends and without taking into
account any compensation, discounts or expenses paid or incurred by the Issuer
for and in the underwriting of, or otherwise in connection with, the issuance
thereof). In connection with any merger or consolidation in which the Issuer is
the surviving corporation (other than any consolidation or merger in which the
previously outstanding shares of Common Stock of the Issuer shall be changed to
or exchanged for the stock or other securities of another corporation), the
amount of consideration therefore shall be, deemed to be the fair value, as
determined reasonably and in good faith by the Board, and acceptable to the
Holder, of such portion of the assets and business of the non-surviving
corporation as the Board may determine to be attributable to such shares of
Common Stock or Common Stock Equivalents, as the case may be. The consideration
for any Additional Shares of Common Stock issuable pursuant to any warrants or
other rights to subscribe for or purchase the same shall be the consideration
received by the Issuer for issuing such warrants or other rights plus the
additional consideration payable to the Issuer upon exercise of such warrants or
other rights. The consideration for any Additional Shares of Common Stock
issuable pursuant to the terms of any Common Stock Equivalents shall be the
consideration received by the Issuer for issuing warrants or other rights to
subscribe for or purchase such Common Stock Equivalents, plus the consideration
paid or payable to the Issuer in respect of the subscription for or purchase of
such Common Stock Equivalents, plus the additional consideration, if any,
payable to the Issuer upon the exercise of the right of conversion or exchange
in such Common Stock Equivalents. In the event of any consolidation or merger of
the Issuer in which the Issuer is not the surviving corporation or in which the
previously outstanding shares of Common Stock of the Issuer shall be changed
into or exchanged for the stock or other securities of another corporation, or
in the event of any sale of all or substantially all of the assets of the Issuer
for stock or other securities of any corporation, the Issuer shall be deemed to
have issued a number of shares of its Common Stock for stock or securities or
other property of the other corporation computed on the basis of the actual
exchange ratio on which the transaction was predicated, and for a consideration
equal to the fair market value on the date of such transaction of all such stock
or securities or other property of the other corporation. In the event any
consideration received by the Issuer for any securities consists of property
other than cash, the fair market value thereof at the time of issuance or as
otherwise applicable shall be as determined in good faith by the Board. In the
event Common Stock is issued with other shares or securities or other assets of
the Issuer for consideration which covers both, the consideration computed as
provided in this Section 4(g)(i) shall be allocated among such securities and
assets as determined in good faith by the Board.

     

    (ii)
  When
Adjustments to Be Made. The adjustments required by this Section 4 shall
be made whenever and as often as any specified event requiring an adjustment
shall occur, except that any adjustment of the number of shares of Common Stock
for which this Warrant is exercisable that would otherwise be required may be
postponed (except in the case of a subdivision or combination of shares of the
Common Stock, as provided for in Section 4(b)) up to, but not beyond the date of
exercise if such adjustment either by itself or with other adjustments not
previously made adds or subtracts less than one percent (1%) of the shares of
Common Stock for which this Warrant is exercisable immediately prior to the
making of such adjustment. Any adjustment representing a change of less than
such minimum amount (except as aforesaid) which is postponed shall be carried
forward and made as soon as such adjustment, together with other adjustments
required by this Section 4 and not previously made, would result in a minimum
adjustment or on the date of exercise. For the purpose of any adjustment, any
specified event shall be deemed to have occurred at the close of business on the
date of its occurrence.

     

    (iii)
  Fractional
Interests. In computing adjustments under this Section 4, fractional
interests in Common Stock shall be taken into account to the nearest one
one-hundredth (1/100th) of a share.

     

    (iv)
  When Adjustment
Not Required. If the Issuer shall take a record of the holders of its
Common Stock for the purpose of entitling them to receive a dividend or
distribution or subscription or purchase rights and shall, thereafter and before
the distribution to stockholders thereof, legally abandon its plan to pay or
deliver such dividend, distribution, subscription or purchase rights, then
thereafter no adjustment shall be required by reason of the taking of such
record and any such adjustment previously made in respect thereof shall be
rescinded and annulled.

     

    (h)
  Form of Warrant
after Adjustments. The form of this Warrant need not be changed because
of any adjustments in the Warrant Price or the number and kind of Securities
purchasable upon the exercise of this Warrant.

    
      
         

      

      
        8

        
          

        

      

      
         

      

    

     

                (i)
  Escrow of
Warrant Stock. If after any property becomes distributable pursuant to
this Section 4 by reason of the taking of any record of the holders of Common
Stock, but prior to the occurrence of the event for which such record is taken,
and the Holder exercises this Warrant, any shares of Common Stock issuable upon
exercise by reason of such adjustment shall be deemed the last shares of Common
Stock for which this Warrant is exercised (notwithstanding any other provision
to the contrary herein) and such shares or other property shall be held in
escrow for the Holder by the Issuer to be issued to the Holder upon and to the
extent that the event actually takes place, upon payment of the current Warrant
Price. Notwithstanding any other provision to the contrary herein, if the event
for which such record was taken fails to occur or is rescinded, then such
escrowed shares shall be cancelled by the Issuer and escrowed property
returned.

     

    5.  
Notice of
Adjustments. Whenever the Warrant Price or Warrant Share Number shall be
adjusted pursuant to Section 4 hereof (for purposes of this Section 5, each an
“adjustment”),
the Issuer shall cause its Chief Financial Officer or other authorized officer,
as the case may be, to prepare and execute a certificate setting forth, in
reasonable detail, the event requiring the adjustment, the amount of the
adjustment, the method by which such adjustment was calculated (including a
description of the basis on which the Board made any determination hereunder),
and the Warrant Price and Warrant Share Number after giving effect to such
adjustment, and shall cause copies of such certificate to be delivered to the
Holder of this Warrant promptly after each adjustment. Any dispute between the
Issuer and the Holder of this Warrant with respect to the matters set forth in
such certificate may at the option of the Holder of this Warrant be submitted to
an Independent Appraiser, provided that the
Issuer shall have ten (10) days after receipt of notice from such Holder of its
selection of such firm to object thereto, in which case such Holder shall select
another such firm and the Issuer shall have no such right of objection. The
Independent Appraiser selected by the Holder of this Warrant as provided in the
preceding sentence shall be instructed to deliver a written opinion as to such
matters to the Issuer and such Holder within thirty (30) days after submission
to it of such dispute. Such opinion shall be final and binding on the parties
hereto. The reasonable costs and expenses of the Independent Appraiser in making
such determination shall be paid by the Issuer, in the event the Holder's
calculation was correct, or by the Holder, in the event the Issuer’s calculation
was correct, or equally by the Issuer and the Holder in the event that neither
the Issuer's or the Holder's calculation was correct.

     

    6.  
Fractional
Shares. No fractional shares of Warrant Stock will be issued in
connection with any exercise hereof, but in lieu of such fractional shares, the
Issuer shall, at its option, (a) pay an amount in cash equal to the Warrant
Price multiplied by such fraction or (b) round the number of shares to be issued
upon exercise up to the nearest whole number of shares.

     

    7.  
Ownership Cap and
Exercise Restriction. Notwithstanding anything to the contrary set forth
in this Warrant, at no time may the Holder exercise this Warrant if the number
of shares of Common Stock to be issued pursuant to such exercise would cause the
number of shares of Common Stock beneficially owned by the Holder at such time
to exceed, when aggregated with all other shares of Common Stock owned by the
Holder and its affiliates at such time, the number of shares of Common Stock
which would result in the Holder, its affiliates, any investment manager having
discretionary investment authority over the accounts or assets of the Holder and
its affiliates, or any other persons whose beneficial ownership of Common Stock
would be aggregated for purposes of Section 13(d) and Section 16 of the Exchange
Act, beneficially owning (as determined in accordance with Section 13(d) of the
Exchange Act and the rules thereunder) in excess of 9.9% of the then issued and
outstanding shares of Common Stock; provided, however, that upon
the Holder providing the Issuer with sixty-one (61) days notice (pursuant to
this certificate) (the “Waiver Notice”) that
the Holder would like to waive this Section 7 with regard to any or all shares
of Common Stock issuable upon exercise of this Warrant, this Section 7 shall be
of no force or effect with regard to those shares of Common Stock referenced in
the Waiver Notice; provided, further, that during
the sixty-one (61) day period prior to the Termination Date, the Holder may
waive this Section 7 by providing a Waiver Notice at any time during such
sixty-one (61) day period; provided, further, that any
Waiver Notice provided during the sixty-one (61) day period prior to the
Termination Date will not be effective until the Termination Date.

     

                8.
  Registration
Rights. The Holder of this Warrant is entitled to the benefit of certain
registration rights with respect to the shares of Warrant Stock issuable upon
the exercise of this Warrant pursuant to that certain Subscription Agreement, of
even date herewith, by and among the Issuer and Persons listed on Schedule I thereto
(the “Subscription
Agreement”) and the registration rights with respect to the shares of
Warrant Stock issuable upon the exercise of this Warrant by any subsequent
Holder may only be assigned in accordance with the terms and provisions
therein.

    
      
         

      

      
        9

        
          

        

      

      
         

      

    

    

    9.  
Definitions.
For the purposes of this Warrant, the following terms have the following
meanings:

     

    “Additional Shares of Common
Stock” means all shares of Common Stock issued by the Issuer after the
Original Issue Date, and all shares of Other Common, if any, issued by the
Issuer after the Original Issue Date, except: (i) securities issued (other than
for cash) in connection with a strategic merger, acquisition, or consolidation,
provided that the issuance of such securities in connection with such strategic
merger, acquisition, or consolidation has been approved in advance by the
Majority Holders, (ii) securities issued pursuant to the conversion or exercise
of convertible or exercisable securities issued or outstanding on or prior to
the date of the Subscription Agreement or issued pursuant to the Subscription
Agreement (so long as the conversion or exercise price in such securities are
not amended to lower such price and/or adversely affect the Holders) which have
previously been disclosed to the Holder, (iii) the Warrant Stock, (iv)
securities issued in connection with bona fide strategic license agreements or
other partnering arrangements so long as such issuances are not for the purpose
of raising capital and provided that the issuance of such securities in
connection with such bona fide strategic license agreements or other partnering
arrangements has been approved in advance by the Majority Holders, (v) Common
Stock issued or the issuance or grants of options to purchase Common Stock
pursuant to the Issuer’s equity incentive plans outstanding as they exist on the
date of the Subscription Agreement, (vi) the issuance or grants of options to
purchase Common Stock to employees, officers or directors of the Issuer pursuant
to any equity incentive plan duly adopted by the Board or a committee thereof
established for such purpose so long as such issuances in the aggregate do not
exceed ten percent (10%) of the total number of then issued and outstanding
shares of Common Stock, unless approved by the Majority Holders, and the
specified price at which the options may be exercised is equal to or greater
than the Per Share Market Value as of the date of such grant, (vii) any
warrants, shares of Common Stock or other securities issued to a placement agent
and its designees for the transactions contemplated by the Subscription
Agreement, which have been previously disclosed to the Holder or in any other
sales of the Issuer’s securities and any securities issued in connection with
any financial advisory agreements of the Issuer and the shares of Common Stock
issued upon exercise of any such warrants or conversions of any such other
securities and (viii) any warrants, shares of Common Stock or other securities
issued to any advisor or consultant to the Company that are outstanding as of
the date of the Subscription Agreement, or are to be issued pursuant to the
terms of an engagement letter or other contractual obligation as of the date of
the Subscription Agreement, and which have previously been disclosed to the
Holder. .

     

    “Board” shall mean the
Board of Directors of the Issuer.

     

     “Capital Stock” means
and includes (i) any and all shares, interests, participations or other
equivalents of or interests in (however designated) corporate stock, including,
without limitation, shares of preferred or preference stock, (ii) all
partnership interests (whether general or limited) in any Person which is a
partnership, (iii) all membership interests or limited liability company
interests in any limited liability company, and (iv) all equity or ownership
interests in any Person of any other type.

     

    “Certificate of
Incorporation” means the Certificate of Incorporation of the Issuer as in
effect on the Original Issue Date, and as hereafter from time to time amended,
modified, supplemented or restated in accordance with the terms hereof and
thereof and pursuant to applicable law.

     

     “Common Stock” means
the Common Stock, $0.00001 par value per share, of the Issuer and any other
Capital Stock into which such stock may hereafter be changed.

     

    “Common Stock
Equivalent” means any Convertible Security or warrant, option or other
right to subscribe for or purchase any Additional Shares of Common Stock or any
Convertible Security.

    

    “Convertible
Securities” means evidences of Indebtedness, shares of Capital Stock or
other Securities which are or may be at any time convertible into or
exchangeable for Additional Shares of Common Stock. The term “Convertible
Security” means one of the Convertible Securities.

     

    
      
        
        

      

      
        10

        
          

        

      

      
        
        

      

    

     

    “Governmental
Authority” means any governmental, regulatory or self-regulatory entity,
department, body, official, authority, commission, board, agency or
instrumentality, whether federal, state or local, and whether domestic or
foreign.

     

    “Holders” mean the
Persons who shall from time to time own any Warrant. The term “Holder” means one
of the Holders.

     

    “Independent
Appraiser” means a nationally recognized or major regional investment
banking firm or firm of independent certified public accountants of recognized
standing (which may be the firm that regularly examines the financial statements
of the Issuer) that is regularly engaged in the business of appraising the
Capital Stock or assets of corporations or other entities as going concerns, and
which is not affiliated with either the Issuer or the Holder of any
Warrant.

     

    “Issuer” means Weikang
Bio-Technology Group Company, Inc., a Nevada corporation, and its
successors.

     

    “Majority Holders”
means at any time the Holders of Warrants exercisable for a majority of the
shares of Warrant Stock issuable under the Warrants at the time
outstanding,.

     

    “Original Issue Date”
means January 20, 2010.

    

    “OTC Bulletin Board”
means the over-the-counter electronic bulletin board.

    

    “Other Common” means
any other Capital Stock of the Issuer of any class which shall be authorized at
any time after the date of this Warrant (other than Common Stock) and which
shall have the right to participate in the distribution of earnings and assets
of the Issuer without limitation as to amount.

     

    “Outstanding Common
Stock” means, at any given time, the aggregate amount of outstanding
shares of Common Stock, assuming full exercise, conversion or exchange (as
applicable) of all options, warrants and other Securities which are convertible
into or exercisable or exchangeable for, and any right to subscribe for, shares
of Common Stock that are outstanding at such time.

     

    “Person” means an
individual, corporation, limited liability company, partnership, joint stock
company, trust, unincorporated organization, joint venture, Governmental
Authority or other entity of whatever nature.

     

    “Per Share Market
Value” means on any particular date (a) the last closing price per share
of the Common Stock on such date on the Trading Market or another registered
national stock exchange on which the Common Stock is then listed, or if there is
no closing price on such date, then the closing bid price on such date, or if
there is no closing bid price on such date, then the closing price on such
exchange or quotation system on the date nearest preceding such date, or (b) if
the Common Stock is not listed then on a Trading Market or any registered
national stock exchange, the last closing price for a share of Common Stock in
the over-the-counter market, as reported by the Trading Market or any registered
national stock exchange or in the National Quotation Bureau Incorporated or
similar organization or agency succeeding to its functions of reporting prices)
at the close of business on such date, or if there is no closing price on such
date, then the closing bid price on such date, or (c) if the Common Stock is not
then reported by the Trading Market or any registered national stock exchange or
in the National Quotation Bureau Incorporated (or similar organization or agency
succeeding to its functions of reporting prices), then the average of the “Pink
Sheet” quotes for the five (5) Trading Days preceding such date of
determination, or (d) if the Common Stock is not then publicly traded the fair
market value of a share of Common Stock as determined by an Independent
Appraiser selected in good faith by the Majority Holders; provided, however , that the
Issuer, after receipt of the determination by such Independent Appraiser, shall
have the right to select an additional Independent Appraiser, in which case, the
fair market value shall be equal to the average of the determinations by each
such Independent Appraiser; and provided, further, that all
determinations of the Per Share Market Value shall be appropriately adjusted for
any stock dividends, stock splits or other similar transactions during such
period. The determination of fair market value by an Independent Appraiser shall
be based upon the fair market value of the Issuer determined on a going concern
basis as between a willing buyer and a willing seller and taking into account
all relevant factors determinative of value, and shall be final and binding on
all parties. In determining the fair market value of any shares of Common Stock,
no consideration shall be given to any restrictions on transfer of the Common
Stock imposed by agreement or by federal or state securities laws, or to the
existence or absence of, or any limitations on, voting rights.

     

    
      
        
        

      

      
        11

        
          

        

      

      
        
        

      

    

     

    “Subscription
Agreement” means the Subscription Agreement dated as of January 20, 2010,
among the Issuer and the Purchasers.

     

    “Purchasers” means the
purchasers of the Common Stock and Warrants (as defined in the Subscription
Agreement), issued by the Issuer pursuant to the Subscription
Agreement.

     

    “Securities” means any
debt or equity securities of the Issuer, whether now or hereafter authorized,
any instrument convertible into or exchangeable for Securities or a Security,
and any option, warrant or other right to purchase or acquire any Security.
“Security” means one of the Securities.

     

    “Securities Act” means
the Securities Act of 1933, as amended, or any similar federal statute then in
effect.

     

    “Subsidiary” means any
corporation at least 50% of whose outstanding Voting Stock shall at the time be
owned directly or indirectly by the Issuer or by one or more of its
Subsidiaries, or by the Issuer and one or more of its Subsidiaries.

     

    “Term” has the meaning
specified in Section 1 hereof.

     

    “Trading Day” means
(a) a day on which the Common Stock is traded on a Trading Market, or (b) if the
Common Stock is not traded on a Trading Market, a day on which the Common Stock
is quoted in the over-the-counter market as reported by the National Quotation
Bureau Incorporated (or any similar organization or agency succeeding its
functions of reporting prices); provided , however , that in the
event that the Common Stock is not listed or quoted as set forth in (a) or (b)
hereof, then Trading Day shall mean any day except Saturday, Sunday and any day
which shall be a legal holiday or a day on which banking institutions in the
State of New York are authorized or required by law or other government action
to close.

     

    “Trading Market” means
the following markets or exchanges on which the Common Stock is listed or quoted
for trading on the date in question: the American Stock Exchange, the Nasdaq
Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the
New York Stock Exchange or the OTC Bulletin Board.

     

    “Voting Stock” means,
as applied to the Capital Stock of any corporation, Capital Stock of any class
or classes (however designated) having ordinary voting power for the election of
a majority of the members of the Board of Directors (or other governing body) of
such corporation, other than Capital Stock having such power only by reason of
the happening of a contingency.

     

    “VWAP” means, for any
date, the price determined by the first of the following clauses that applies:
(a) if the Common Stock is then listed or quoted on a Trading Market, the daily
volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed
or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m.
New York City time to 4:00 p.m. New York City time); (b) if the OTC Bulletin
Board is not a Trading Market, the volume weighted average price of the Common
Stock for such date (or the nearest preceding date) on the OTC Bulletin Board;
(c) if the Common Stock is not then listed or quoted on the OTC Bulletin Board
and if prices for the Common Stock are then reported in the "Pink Sheets"
published by Pink Sheets, LLC (or a similar organization or agency succeeding to
its functions of reporting prices), the most recent bid price per share of the
Common Stock so reported; or (d) in all other cases, the fair market value of a
share of Common Stock as determined by an Independent Appraiser selected in good
faith by the Majority Holders, the fees and expenses of which shall be paid by
the Issuer.

     

    
      
        
        

      

      
        12

        
          

        

      

      
        
        

      

    

     

    “Warrants” means the
Warrants issued and sold pursuant to the Subscription Agreement, including,
without limitation, this Warrant, and any other warrants of like tenor issued in
substitution or exchange for any thereof pursuant to the provisions of Section
2(c), 2(d) or 2(e) hereof or of any of such other Warrants.

     

    “Warrant Price”
initially means $5.00 per share as such price may be adjusted from time to time
as shall result from the adjustments specified in this Warrant, including
Section 4 hereto.

     

    “Warrant Share Number”
means at any time the aggregate number of shares of Warrant Stock which may at
such time be purchased upon exercise of this Warrant, after giving effect to all
prior adjustments and increases to such number made or required to be made under
the terms hereof.

    

    “Warrant Stock” means
Common Stock issuable upon exercise of any Warrant or Warrants or otherwise
issuable pursuant to any Warrant or Warrants.

     

    10.
  Other
Notices. In case at any time:

     

    (a)
  the Issuer shall make any distributions to the holders of Common Stock;
or

     

    (b)
  the Issuer shall authorize the granting to all holders of its Common
Stock of rights to subscribe for or purchase any shares of Capital Stock of any
class or other rights; or

     

    (c)
  there shall be any reclassification of the Capital Stock of the Issuer;
or

     

    (d)
  there shall be any capital reorganization by the Issuer; or

     

    (e)
  there shall be any (i) consolidation or merger involving the Issuer or
(ii) sale, transfer or other disposition of all or substantially all of the
Issuer’s property, assets or business (except a merger or other reorganization
in which the Issuer shall be the surviving corporation and its shares of Capital
Stock shall continue to be outstanding and unchanged and except a consolidation,
merger, sale, transfer or other disposition involving a wholly-owned
Subsidiary); or

     

    (f)
  there shall be a voluntary or involuntary dissolution, liquidation or
winding-up of the Issuer or any partial liquidation of the Issuer or
distribution to holders of Common Stock;

     

    then, in
each of such cases, the Issuer shall give written notice to the Holder of the
date on which (i) the books of the Issuer shall close or a record shall be taken
for such dividend, distribution or subscription rights or (ii) such
reorganization, reclassification, consolidation, merger, disposition,
dissolution, liquidation or winding-up, as the case may be, shall take place.
Such notice also shall specify the date as of which the holders of Common Stock
of record shall participate in such dividend, distribution or subscription
rights, or shall be entitled to exchange their certificates for Common Stock for
securities or other property deliverable upon such reorganization,
reclassification, consolidation, merger, disposition, dissolution, liquidation
or winding-up, as the case may be. Such notice shall be given at least twenty
(20) days prior to the action in question and not less than ten (10) days prior
to the record date or the date on which the Issuer’s transfer books are closed
in respect thereto. This Warrant entitles the Holder to receive copies of all
financial and other information distributed or required to be distributed to the
holders of the Common Stock.

     

    11.
  Amendment and
Waiver. Any term, covenant, agreement or condition in this Warrant may be
amended, or compliance therewith may be waived (either generally or in a
particular instance and either retroactively or prospectively), by a written
instrument or written instruments executed by the Issuer and the Majority
Holders; provided , however , that no
such amendment or waiver shall reduce the Warrant Share Number, increase the
Warrant Price, shorten the period during which this Warrant may be exercised or
modify any provision of this Section 11 without the consent of the Holder of
this Warrant. No consideration shall be offered or paid to any person to amend
or consent to a waiver or modification of any provision of this Warrant unless
the same consideration is also offered to all holders of the
Warrants.

     

    
      
        
        

      

      
        13

        
          

        

      

      
        
        

      

    

    

               12.
  Governing Law;
Jurisdiction. This Warrant shall be governed by and construed in
accordance with the internal laws of the State of New York, without giving
effect to any of the conflicts of law principles which would result in the
application of the substantive law of another jurisdiction. This Warrant shall
not be interpreted or construed with any presumption against the party causing
this Warrant to be drafted. The Issuer and the Holder agree that venue for any
dispute arising under this Warrant will lie exclusively in the state or federal
courts located in New York, and the parties irrevocably waive any right to raise
forum non conveniens or any other argument that New York is not the proper
venue. The Issuer and the Holder irrevocably consent to personal jurisdiction in
the state and federal courts of the state of New York. The Issuer and the Holder
consent to process being served in any such suit, action or proceeding by
mailing a copy thereof via registered or certified mail or overnight delivery
(with evidence of delivery) to such party at the address in effect for notices
to it under this Warrant and agree that such service shall constitute good and
sufficient service of process and notice thereof. Nothing in this Section 12
shall affect or limit any right to serve process in any other manner permitted
by law. The Issuer and the Holder hereby agree that the prevailing party in any
suit, action or proceeding arising out of or relating to this Warrant or the
Subscription Agreement, shall be entitled to reimbursement for reasonable legal
fees from the non-prevailing party. The parties hereby waive all rights to a
trial by jury.

     

    13.
  Notices.
Any notice, demand, request, waiver or other communication required or permitted
to be given hereunder shall be in writing and shall be effective (a) immediately
upon hand delivery, telecopy or facsimile at the address or number designated
below (if delivered on a business day during normal business hours where such
notice is to be received), or the first business day following such delivery (if
delivered other than on a business day during normal business hours where such
notice is to be received) or (b) on the second business day following the date
of mailing by express courier service, fully prepaid, addressed to such address,
or upon actual receipt of such mailing, whichever shall first occur. The
addresses for such communications shall be:

    

    
      
        
          
            	
                    If
      to the Issuer:

                  	 	
                    Weikang
      Bio-Technology Group Company, Inc.

                    Attn:
      Mr. Yin Wang, Chairman

                    No.
      365 Chengde Street, Daowai District, Harbin

                    Heilongjiang
      Province, PRC 150020

                    facsimile:
      +

                  
	 
      	 	 
      
	
                    with
      copies (which copies

                    shall
      not constitute notice)

                    to:

                  	 	 
      
	 
      	 	 
      
	
                    If to any Holder:

                  	 	
                    At
      the address of such Holder set forth on Exhibit A to this Agreement, with
      copies to Holder’s counsel as set forth on Exhibit A or as specified in
      writing by such Holder with copies to:

                  
	 
      	 	 
      
	
                    with
      copies (which copies

                    shall
      not constitute notice)

                    to:

                  	 	
                    Anslow
      & Jaclin LLP

                    195
      Route 9 South, 2nd
      Floor

                    Manalapan,
      NJ 07726

                    Attn:
      Kristina M. Trauger, Esq.

                    Tel.
      No.: (732) 409-1212

                    Fax
      No: (732) 577-1188

                  

          

           

          
            
              
              

            

            
              14

              
                

              

            

            
              
              

            

          

        

      

    

     

    Any party
hereto may from time to time change its address for notices by giving at least
ten (10) days written notice of such changed address to the other party
hereto.

     

    14.
  Warrant
Agent. The Issuer may, by written notice to the Holder of this Warrant,
appoint an agent having an office in New York, New York for the purpose of
issuing shares of Warrant Stock on the exercise of this Warrant pursuant to
subsection (b) of Section 2 hereof, exchanging this Warrant pursuant to
subsection (d) of Section 2 hereof or replacing this Warrant pursuant to
subsection (d) of Section 3 hereof, or any of the foregoing, and thereafter any
such issuance, exchange or replacement, as the case may be, shall be made at
such office by such agent.

     

    15.   Mandatory Exercise
Provision.  In the event that (i) the VWAP for the previous
twenty (20) Trading Days is above $6.50, and (iii) the average daily volume of
the Issuer’s Common Stock for the previous twenty (20) Trading Days exceeds
20,000 shares per day, then the Issuer, upon ten (10) business days prior
written notice (the “Notice Period”) given
to the Holders within three business days immediately following the end of such
twenty (20) Trading Day period, may require the exercise of this Warrant
pursuant to the provisions of Section (2) herein (the “Mandatory Exercise”);
provided that
(i) the Issuer simultaneously requires the exercise of all Series A Warrants on
the same terms, (ii) all of the shares of Common Stock issuable hereunder are
registered pursuant to an effective Registration Statement (as defined in the
Registration Rights Agreement) which at the time of such Mandatory Exercise is
not suspended and for which no stop order is in effect, and pursuant to which
the Holder is able to sell such shares of Common Stock at all times during the
Notice Period and (iii) this Warrant is fully exercisable for the full amount of
Warrant Stock covered hereby notwithstanding the ownership cap and restrictions
set forth in Section 7 hereof (the “Ownership Cap”); provided that the
Mandatory Exercise shall be subject to the Ownership Cap and the Company shall
only be entitled to require the Mandatory Exercise of the warrant up to the
Ownership Cap. Notwithstanding any such notice by the Issuer, the Holder shall
have the right to exercise all, or any portion, of this Warrant prior to the end
of the Notice Period.  The Company shall have the right, but not the
obligation, to exercise the Mandatory Exercise at any time, and from time to
time in accordance with this Section 15, but in no event shall the Company
exercise the right more than once in any thirty (30) Trading Day
period.

    

    16.
  Remedies. The Issuer
stipulates that the remedies at law of the Holder of this Warrant in the event
of any default or threatened default by the Issuer in the performance of or
compliance with any of the terms of this Warrant are not and will not be
adequate and that, to the fullest extent permitted by law, such terms may be
specifically enforced by a decree for the specific performance of any agreement
contained herein or by an injunction against a violation of any of the terms
hereof or otherwise.

     

    17.
  Successors and
Assigns. This Warrant and the rights evidenced hereby shall inure to the
benefit of and be binding upon the successors and assigns of the Issuer, the
Holder hereof and (to the extent provided herein) the Holders of Warrant Stock
issued pursuant hereto, and shall be enforceable by any such Holder or Holder of
Warrant Stock.

     

    18.
  Modification
and Severability. If, in any action before any court or agency legally
empowered to enforce any provision contained herein, any provision hereof is
found to be unenforceable, then such provision shall be deemed modified to the
extent necessary to make it enforceable by such court or agency. If any such
provision is not enforceable as set forth in the preceding sentence, the
unenforceability of such provision shall not affect the other provisions of this
Warrant, but this Warrant shall be construed as if such unenforceable provision
had never been contained herein.

    

    19.    No Rights as
Stockholders. Prior to the exercise of this Warrant, the Holder shall not
have or exercise any rights as a stockholder of the Issuer by virtue of its
ownership of this Warrant.

     

    20.
  Headings. The
headings of the Sections of this Warrant are for convenience of reference only
and shall not, for any purpose, be deemed a part of this Warrant.

     

    [REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]

    
      
         

      

      
        15

        
          

        

      

      
         

      

    

     

                IN
WITNESS WHEREOF, the Issuer has executed this Warrant as of the day and year
first above written.

     

    
      
        
          
            
              
                	
                        WEIKANG
      BIO-TECHNOLOGY GROUP COMPANY, INC.

                      	 
	 
      	 
      	 
	
                        By:

                      	 
      	 
	 
      	
                        Name:

                      	 
	 
      	
                        Title:

                      	 

              

            

          

        

      

    

     

    
      
         

      

      
        16

        
          

        

      

      
         

      

    

     

    EXERCISE
FORM

    SERIES B
WARRANT

     

    WEIKANG
BIO-TECHNOLOGY GROUP COMPANY, INC.

     

    The
undersigned _______________, pursuant to the provisions of the within Warrant,
hereby elects to purchase _____ shares of Common Stock of
________________________________ covered by the within Warrant.

     

    
      
        	
                Dated:

              	 
      	 
      	
                Signature  

              	 
      
	 
      	 
      	 
      	 
      	 
      
	 
      	 
      	 
      	
                Address

              	 
      
	 
      	 
      	 
      	 
      	 
      
	 
      	 
      	 
      	 
      	 
      

      

    

     

    Number of
shares of Common Stock beneficially owned or deemed beneficially owned by the
Holder on the date of Exercise: _________________________

     

    The
undersigned is an “accredited investor” as defined in Regulation D under the
Securities Act of 1933, as amended.

     

    The
undersigned intends that payment of the Warrant Price shall be made as (check
one):

     

    Cash
Exercise_______

     

    Cashless
Exercise_______

     

    If the
Holder has elected a Cash Exercise, the Holder shall pay the sum of $________ by
certified or official bank check (or via wire transfer) to the Issuer in
accordance with the terms of the Warrant.

     

    If the
Holder has elected a Cashless Exercise, a certificate shall be issued to the
Holder for the number of shares equal to the whole number portion of the product
of the calculation set forth below, which is ___________. The Issuer shall pay a
cash adjustment in respect of the fractional portion of the product of the
calculation set forth below in an amount equal to the product of the fractional
portion of such product and the Per Share Market Value on the date of exercise,
which product is ____________.

     

    X = Y -
(A)(Y)               

    B                    

     

    Where:

     

    The
number of shares of Common Stock to be issued to the Holder
__________________(“X”).

     

    The
number of shares of Common Stock purchasable upon exercise of all of the Warrant
or, if only a portion of the Warrant is being exercised, the portion of the
Warrant being exercised ___________________________ (“Y”).

     

    The
Warrant Price ______________ (“A”).

     

    The Per
Share Market Value of one share of Common Stock _______________________
(“B”).

    
      
         

      

      
        17

        
          

        

      

      
         

      

    

    ASSIGNMENT

     

    FOR VALUE
RECEIVED, _________________ hereby sells, assigns and transfers unto
__________________ the within Warrant and all rights evidenced thereby and does
irrevocably constitute and appoint _____________, attorney, to transfer the said
Warrant on the books of the within named corporation.

     

    
      
        	
                Dated:

              	 
      	 
      	
                Signature

              	 
      
	 
      	 
      	 
      	 
      	 
      
	 
      	 
      	 
      	
                Address

              	 
      
	 
      	 
      	 
      	 
      	 
      
	 
      	 
      	 
      	 
      	 
      

      

    

     

    PARTIAL
ASSIGNMENT

     

    FOR VALUE
RECEIVED, _________________ hereby sells, assigns and transfers unto
__________________ the right to purchase _________ shares of Warrant Stock
evidenced by the within Warrant together with all rights therein, and does
irrevocably constitute and appoint ___________________, attorney, to transfer
that part of the said Warrant on the books of the within named
corporation.

     

    
      
        	
                Dated:

              	 
      	 
      	
                Signature

              	 
      
	 
      	 
      	 
      	 
      	 
      
	 
      	 
      	 
      	
                Address

              	 
      
	 
      	 
      	 
      	 
      	 
      
	 
      	 
      	 
      	 
      	 
      

      

    

     

    FOR USE
BY THE ISSUER ONLY:

     

    This
Warrant No. W-___ canceled (or transferred or exchanged) this _____ day of
___________, _____, shares of Common Stock issued therefor in the name of
_______________, Warrant No. W-_____ issued for ____ shares of Common Stock in
the name of _______________.

    
      
         

      

      
        18INVESTOR
RELATIONS ESCROW AGREEMENT

    

    This
AGREEMENT (the “Agreement”) made as of January
20, 2010 by and between Weikang Bio-Technology Group Company, Inc., a Nevada
corporation (the “Issuer”), No. 365 Chengde
Street, Daowai District, Harbin, Heilongjiang Province, PRC 150020, Anslow &
Jaclin, LLP, 195 Route 9 South, 2nd
Floor, Manalapan, NJ 07726 (the “Escrow Agent”) and Opus
Holdings Three, Ltd. (the “Subscriber
Representative”).

    

    WITNESETH:

    

    WHEREAS, the Issuer is
offering to the subscribers on a “best efforts” basis, up to $5,000,000 of its
common stock, $0.0001 par value per share (the “Purchased Shares”) at a per
share purchase price of $1.70 and Series A and Series B common stock purchase
warrants (the “Offering”), in reliance upon
an exemption from securities registration afforded by the provisions of Section
4(2), Section 4(6), Regulation D and/or Regulation S as promulgated by the
United States Securities and Exchange Commission under the Securities Act of
1933, as amended;

    

    WHEREAS, the Issuer proposes
to establish an escrow account (the “Escrow Account”), which shall
include One Hundred Fifty Thousand Dollars ($150,000) of the Offering proceeds
from the initial closing to be used for investor relations fees (the “Escrow Funds”); and the Escrow
Agent is willing to establish the Escrow Account on the terms and subject to the
conditions hereinafter set forth;

    

    WHEREAS, the Subscriber
Representative has appointed Ryan Cravey as the IR representative (the “IR Representative”) to act on
behalf of the Issuer in designating the disbursement of the Escrow Funds to an
investor relations firm to be designated by the Subscriber
Representative.

    

    NOW, THEREFORE, in
consideration of the premises and mutual covenants herein contained, the parties
hereto hereby agree as follows:

    

    1.           Appointment of Escrow
Agent. The Issuer and Subscriber Representative hereby appoint Anslow
& Jaclin, LLP as escrow agent to act in accordance with the terms and
conditions set forth in this Agreement, and the Escrow Agent hereby accepts such
appointment and agrees to establish the Bank Account on the terms and subject to
the conditions hereinafter set forth.

    

    2.           Establishment of the Bank
Account. The Escrow Agent shall establish a non-interest-bearing bank
account at the branch of the Bank selected by the Escrow Agent (heretofore
defined as the “Bank
Account”). The purpose of the Bank Account is for (a) the deposit of the
Escrow Funds by the Issuer, and (b) the disbursement of collected funds, all as
described herein.

    

    3.           Delivery of the Escrow
Funds. The Issuer hereby directs the Escrow Agent to allocate the Escrow
Funds separately from the proceeds of the Offering at the closing, to be held
and disbursed by the Escrow Agent as provided in this Agreement. The Escrow
Funds shall be held by the Escrow Agent in the Bank Account as
follows:

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    
      
        	
                  
      Bank Address:

              	
                Wachovia
      Bank NA

              
	 
      	
                800
      West Main Street

              
	 
      	
                Freehold,
      New Jersey 07726

              
	
                  
      ABA No.: 031201467

              
	
                  
      Account: Anslow & Jaclin LLP Attorney Trust Account

              
	
                  
      Account No.: 2000013292968

              
	
                  
      Attn: Kristina L. Trauger, Esq.

              
	
                  
      Reference: Weikang Bio-Technology Group Company,
  Inc.

              

      

    

    

    4.           Disbursements from the Bank
Account. The Escrow Agent shall hold the Escrow Funds in accordance with
the terms of this Agreement. The Subscriber Representative will appoint an
individual (the “IR
Representative”) to designate the disbursement of the Escrow Funds to an
investor relations firm chosen by the Subscriber Representative. The Escrow
Agent shall receive a disbursement approval form signed by the IR Representative
for any disbursements made from the Escrow Account. If the entire Escrow Funds
are not disbursed within two (2) years from the date hereof, the balance of the
Escrow Funds will be returned to the Issuer.

    

    5.           Duration. This
Agreement shall terminate upon the disbursement of the entire Escrow Funds in
accordance with Section 4.

    

    6.           Interpleader. Should
any controversy arise among the parties hereto with respect to this Agreement or
with respect to the right to receive the Escrow Funds, the Escrow Agent shall
have the right to consult counsel and/or to institute an appropriate
interpleader action to determine the rights of the parties. The Escrow Agent is
also hereby authorized to institute an appropriate interpleader action upon
receipt of a written letter of direction executed by the parties so directing
Escrow Agent. If the Escrow Agent is directed to institute an appropriate
interpleader action, it shall institute such action not prior to thirty (30)
days after receipt of such letter of direction and not later than sixty (60)
days after such date. Any interpleader action instituted in accordance with this
Section 6 shall be filed in any
court of competent jurisdiction in New York, New York, and the Escrow Funds in
dispute shall be deposited with the court and in such event Escrow Agent shall
be relieved of and discharged from any and all obligations and liabilities under
and pursuant to this Agreement with respect to the Escrow Funds.

    

    7.           Exculpation and
Indemnification of Escrow Agent.

    

    7.1           The
Escrow Agent is not a party to, and is not bound by or charged with notice of
any agreement out of which this escrow may arise. The Escrow Agent acts under
this Agreement as a depositary only and is not responsible or liable in any
manner whatsoever for the sufficiency, correctness, genuineness or validity of
the subject matter of the escrow, or any part thereof, or for the form or
execution of any notice given by any other party hereunder, or for the identity
or authority of any person executing any such notice. The Escrow Agent will have
no duties or responsibilities other than those expressly set forth herein. The
Escrow Agent will be under no liability to anyone by reason of any failure on
the part of any party hereto (other than the Escrow Agent) or any maker,
endorser or other signatory of any document to perform such person’s or entity’s
obligations hereunder or under any such document. Except for this Agreement and
instructions to the Escrow Agent pursuant to the terms of this Agreement, the
Escrow Agent will not be obligated to recognize any agreement between or among
any or all of the persons or entities referred to herein, notwithstanding its
knowledge thereof.

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    

    7.2           The
Escrow Agent will not be liable for any action taken or omitted by it, or any
action suffered by it to be taken or omitted, in good faith and in the exercise
of its own best judgment, and may rely conclusively on, and will be protected in
acting upon, any order, notice, demand, certificate, or opinion or advice of
counsel (including counsel chosen by the Escrow Agent), statement, instrument,
report or other paper or document (not only as to its due execution and the
validity and effectiveness of its provisions, but also as to the truth and
acceptability of any information therein contained) which is reasonably believed
by Escrow Agent to be genuine and to be signed or presented by the proper person
or persons. The duties and responsibilities of the Escrow Agent hereunder shall
be determined solely by the express provisions of this Agreement and no other or
further duties or responsibilities shall be implied, including, but not limited
to, any obligation under or imposed by any laws of the State of New York upon
fiduciaries.

    

    7.3           The
Escrow Agent will be indemnified and held harmless, jointly and severally, by
the Issuer from and against any expenses, including reasonable attorneys’ fees
and disbursements, damages or losses suffered by the Escrow Agent in connection
with any claim or demand, which, in any way, directly or indirectly, arises out
of or relates to this Agreement or the services of Escrow Agent hereunder;
except, that if the Escrow Agent is guilty of willful misconduct, fraud or gross
negligence under this Agreement, then the Escrow Agent will bear all losses,
damages and expenses arising as a result of such willful misconduct, fraud or
gross negligence. Promptly after the receipt by the Escrow Agent of notice of
any such demand or claim or the commencement of any action, suit or proceeding
relating to such demand or claim, the Escrow Agent will notify the other parties
hereto in writing. For the purposes hereof, the terms “expense” and “loss” will
include all amounts paid or payable to satisfy any such claim or demand, or in
settlement of any such claim, demand, action, suit or proceeding settled with
the express written consent of the parties hereto, and all costs and expenses,
including, but not limited to, reasonable attorneys’ fees and disbursements,
paid or incurred in investigating or defending against any such claim, demand,
action, suit or proceeding. The provisions of this Section 7 shall survive the
termination of this Agreement.

    

    8.           Fees and Expenses.
Upon closing of the Offering, the Issuer shall pay to the Escrow Agent a fee of
$2,500 as reimbursement for agreeing to perform the services set forth in this
Agreement. In addition, the Issuer agrees to pay the Escrow Agent’s costs and
expenses including reasonable attorney’s fees in the event of any dispute or
litigation threatened or commenced which requires the Escrow Agent in its
opinion to refer such matter to its attorneys. Escrow Agent will incur no
liability for any delay reasonably required to obtain such advice of
counsel.

    

    9.           Resignation of Escrow
Agent. At any time, upon five (5) days’ written notice to the Issuer, the
Escrow Agent may resign and be discharged from its duties as escrow agent
hereunder. As soon as practicable after its resignation, the Escrow Agent will
promptly turn over to a successor escrow agent appointed by the Issuer the
Escrow Funds held hereunder upon presentation of a document appointing the new
escrow agent and evidencing its acceptance thereof. If, by the end of the 5-day
period following the giving of notice of resignation by the Escrow Agent, the
Issuer shall have failed to appoint a successor escrow agent, the Escrow Agent
may interplead the Escrow Funds into the registry of any court having
jurisdiction.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    10.         Records. The Escrow
Agent shall maintain accurate records of all transactions hereunder. Promptly
after the termination of this Agreement or as may reasonably be requested by the
parties hereto from time to time before such termination, the Escrow Agent shall
provide the parties hereto, as the case may be, with a complete copy of such
records, certified by the Escrow Agent to be a complete and accurate account of
all such transactions. The authorized representatives of each of the parties
hereto shall have access to such books and records at all reasonable times
during normal business hours upon reasonable notice to the Escrow
Agent.

    

    11.         Notice. All notices,
communications and instructions required or desired to be given under this
Agreement must be in writing and shall be deemed to be duly given if sent by
registered or certified mail, return receipt requested, or overnight courier to
the following addresses:

    

    If to
Escrow Agent:

    

    Anslow +
Jaclin, LLP

    195 Route
9 South, 2nd
Floor

    Manalapan,
NJ 07726

    Attention:
Kristina L. Trauger, Esq.

    

    If to the
Issuer:

    

    Weikang
Bio-Technology Group Company, Inc.

    No. 365
Chengde Street, Daowei District, Harbin

    Heilongjiang
province, PRC 150020

    Attention:
Mr. Yin Wang, Chairman

    

    If to the
Subscriber Representative:

    

    Opus
Holdings Three, Ltd.

    18000
Groeschke Road, Suite F-5

    Houston,
TX 77084

    Attention:
Opus Holdings Three Management, LLC

    Its
General Partner

    Douglas
B. Shaw, Manager

    

    or to
such other address and to the attention of such other person as any of the above
may have furnished to the other parties in writing and delivered in accordance
with the provisions set forth above.

    

    12.         Execution in
Counterparts. This Agreement may be executed in counterparts, each of
which shall be deemed an original, but all of which together shall constitute
one and the same instrument. Facsimile execution and delivery of this Agreement
is legal, valid and binding for all purposes.

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    13.         Assignment and
Modification. This Agreement and the rights and obligations hereunder of
any of the parties hereto may not be assigned without the prior written consent
of the other parties hereto. Subject to the foregoing, this Agreement will be
binding upon and inure to the benefit of each of the parties hereto and their
respective successors and permitted assigns. No other person will acquire or
have any rights under, or by virtue of, this Agreement. No portion of the Escrow
Funds shall be subject to interference or control by any creditor of any party
hereto, or be subject to being taken or reached by any legal or equitable
process in satisfaction of any debt or other liability of any such party hereto
prior to the disbursement thereof to such party hereto in accordance with the
provisions of this Agreement. This Agreement may be changed or modified only in
writing signed by all of the parties hereto.

    

    14.         Applicable Law. This
Agreement shall be governed by and construed with the laws of the State of New
York applicable to contracts made and to be performed therein. Any litigation
concerning the subject matter of this Agreement shall be exclusively prosecuted
in the state or federal courts located in New York, New York, and all parties
consent to the exclusive jurisdiction and venue of those courts.

    

    15.         Headings. The
headings contained in this Agreement are for convenience of reference only and
shall not affect the construction of this Agreement.

    

    16.         Attorneys’ Fees. If
any action at law or in equity, including an action for declaratory relief, is
brought to enforce or interpret the provisions of this Agreement, the prevailing
party shall be entitled to recover reasonable attorneys’ fees from the other
party (unless such other party is the Escrow Agent), which fees may be set by
the court in the trial of such action or may be enforced in a separate action
brought for that purpose, and which fees shall be in addition to any other
relief that may be awarded.

    

    [Signatures
to Follow on Next Page]

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    IN
WITNESS WHEREOF, the undersigned have executed this Agreement as of the day and
year first above written.

    

    
      
        
          
            
              
                	 
      	
                        ANSLOW
      & JACLIN, LLP

                      
	 
      	 
      
	 
      	
                        By: 
      

                      	 /s/ Gregg
      E. Jaclin
	 
      	 
      	
                        Name: 
      

                      	Gregg
      E. Jaclin  
	 
      	 
      	
                        Title:

                      	
                        Partner

                      
	 
      	 
      
	 
      	
                        WEIKANG
      BIO-TECHNOLOGY GROUP

                      
	 
      	      
                        COMPANY,
      INC.

                      
	 	 	 
	 
      	
                        By: 
      

                      	 
      
	 
      	 
      	
                        Name:

                      	 
      
	 
      	 
      	
                        Title:

                      	 
      
	 
      	 
      	 
      	 
      
	 
      	
                        OPUS
      HOLDINGS THREE, LTD.

                      
	 
      	 
      
	 
      	
                        By: 
      

                      	 
      
	 
      	 
      	
                        Name:

                      	 
      
	 
      	 
      	
                        Title:

                      	 
      

              

            

          

        

      

    

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    IN
WITNESS WHEREOF, the undersigned have executed this Agreement as of the day and
year first above written.

    

    
      
        
          
            	 
      	
                    ANSLOW
      & JACLIN, LLP

                  
	 
      	 
      
	 
      	
                    By: 
      

                  	 
      
	 
      	 
      	
                    Name:

                  	 
      
	 
      	 
      	
                    Title:

                  	 
      
	 
      	 
      
	 
      	
                    WEIKANG
      BIO-TECHNOLOGY GROUP

                  
	 
      	
                    COMPANY,
      INC.

                  
	 
      	 
      
	 
      	
                    By: 
      

                  	 
      
	 
      	 
      	
                    Name:

                  	 
      
	 
      	 
      	
                    Title:

                  	 
      
	 
      	 
      
	 
      	
                    OPUS
      HOLDINGS THREE, LP

                  
	 
      	 
      
	 
      	
                    By: 
      

                  	/s/
      Douglas Shaw and /s/ Trevor Ling  
	 
      	 
      	
                    Name: 
      

                  	
                    DOUGLAS
      SHAW AND TREVOR LING, 

                  
	 
      	 
      	
                    Title:

                  	
                    MANAGERS OF
      OPUS HOLDINGS THREE MANAGEMENT, LLC,

                    ITS
      GENERAL
PARTNER

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00167-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00167-of-00352.parquet"}]]